NASDAQ:DFFN Diffusion Pharmaceuticals (DFFN) Stock Price, News & Analysis → At first glance, this chart looks like nonsense… (From The TradingPub) (Ad) Free DFFN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$4.38▼$6.6052-Week Range N/AVolume351,000 shsAverage Volume10,937 shsMarket Capitalization$8.98 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Diffusion Pharmaceuticals alerts: Email Address Ad Paradigm PressBiden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.See his shocking evidence in this new report About Diffusion Pharmaceuticals Stock (NASDAQ:DFFN)Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. The company was founded in 2001 and is based in Charlottesville, Virginia.Read More Ad Wealthpin ProOne trade. One ticker. One week. Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week? Well, then you should click here to see this free training. DFFN Stock News HeadlinesApril 18, 2024 | bbc.co.ukComparing diffusion, osmosis and active transportFebruary 10, 2024 | thestreet.comDiffusion Pharmaceuticals Inc.April 24, 2024 | Stansberry Research (Ad)The "Smart Money" Is Ready for May 1st Are You?Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company. February 8, 2024 | bizjournals.comVertex co-founder Josh Boger joins Boston biotech working on dementia drugDecember 22, 2023 | venturebeat.comStable Video Diffusion is now available through Stability AI APIAugust 16, 2023 | finanznachrichten.deDiffusion Pharmaceuticals Inc.: Diffusion Pharmaceuticals Stockholders Approve Merger with EIP PharmaAugust 16, 2023 | finanznachrichten.deDiffusion Pharmaceuticals Inc.: Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma / Announces 1-for-1.5 Reverse Stock SplitAugust 15, 2023 | finance.yahoo.comDiffusion Pharmaceuticals Stockholders Approve Merger with EIP PharmaApril 24, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…July 24, 2023 | finance.yahoo.comDiffusion Pharmaceuticals Inc. (DFFN) stock forecast and price targetMay 23, 2023 | benzinga.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FOCS, RADI, BGRY, DFFNMarch 31, 2023 | marketwatch.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Diffusion Pharmaceuticals Inc. MergerMarch 30, 2023 | technews.tmcnet.comDFFN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Diffusion Pharmaceuticals Inc. Is Fair to ShareholdersMarch 30, 2023 | msn.comDiffusion to merge with EIP Pharma in all-stock dealMarch 30, 2023 | finance.yahoo.comEIP Pharma and Diffusion Pharmaceuticals Announce Merger Agreement to Create Leading CNS-focused Company Treating Neurodegenerative DiseasesDecember 16, 2022 | markets.businessinsider.comDiffusion's Shareholder LifeSci Supports Company's Strategic Review Process And Director NomineesDecember 16, 2022 | finance.yahoo.comDiffusion Pharmaceuticals Announces Agreement with LifeSci Special OpportunitiesDecember 5, 2022 | finance.yahoo.comDiffusion Pharmaceuticals Sends Letter to Stockholders Highlighting Strength of Board Leadership and Positive Progress in Strategic Review, Cautioning Stockholders Regarding LifeSci’s History of Stockholder Value Destruction and Self-DealingDecember 1, 2022 | finance.yahoo.comDFFN: Strategic Review Underway; Planning to Initiate Phase 2 GBM Trial in 1Q23…November 15, 2022 | finance.yahoo.comDiffusion Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business UpdateNovember 14, 2022 | finance.yahoo.comDiffusion Pharmaceuticals Sees Significant Progress in its Strategic Review ProcessOctober 15, 2022 | forbes.comDiffusion PharmaceuticalsSeptember 29, 2022 | finance.yahoo.comDiffusion Pharmaceuticals Inc. (DFFN)August 17, 2022 | seekingalpha.comDiffusion raised to Buy at H.C. Wainwright after Q2 update on lead assetAugust 17, 2022 | finance.yahoo.comDFFN: Phase 2 GBM Trial to Initiate 2H22…August 11, 2022 | finance.yahoo.comDiffusion Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business UpdateJuly 26, 2022 | finance.yahoo.comDiffusion Pharmaceuticals to Initiate Phase 2 Trial in Patients with Glioblastoma Multiforme Incorporating Innovative Imaging Methodology to Evaluate Tumor OxygenationSee More Headlines Receive DFFN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Diffusion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today4/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:DFFN CUSIPN/A CIK1053691 Webwww.diffusionpharma.com Phone(434) 220-0718Fax434-220-0722Employees13Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,590,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-69.96% Return on Assets-62.98% Debt Debt-to-Equity RatioN/A Current Ratio10.71 Quick Ratio10.71 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.97 per share Price / BookN/AMiscellaneous Outstanding Shares2,040,000Free Float2,003,000Market Cap$8.98 million OptionableNot Optionable Beta1.78 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Robert J. Cobuzzi Jr. (Age 58)Ph.D., Pres & CEO Comp: $691.79kMr. William Robert Elder J.D. (Age 40)Gen. Counsel & Corp. Sec. Comp: $413.92kDr. David Randolph Jones M.D. (Age 60)Sr. Medical Advisor Mr. Harry CookVP of Clinical OperationsMr. Douglas GravattSr. Consultant for ManufacturingMr. Brian D. BollwageSr. Consultant - Regulatory AffairsMore ExecutivesKey CompetitorsAeterna ZentarisNASDAQ:AEZSNuCanaNASDAQ:NCNAMolecular TemplatesNASDAQ:MTEMVirios TherapeuticsNASDAQ:VIRIAkari TherapeuticsNASDAQ:AKTXView All Competitors DFFN Stock Analysis - Frequently Asked Questions How were Diffusion Pharmaceuticals' earnings last quarter? Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) issued its quarterly earnings results on Wednesday, November, 10th. The company reported ($9.00) EPS for the quarter, missing analysts' consensus estimates of ($3.00) by $6.00. When did Diffusion Pharmaceuticals' stock split? Diffusion Pharmaceuticals shares reverse split before market open on Thursday, August 17th 2023. The 1-1.5 reverse split was announced on Thursday, August 17th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, August 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 67 shares after the split. What other stocks do shareholders of Diffusion Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Diffusion Pharmaceuticals investors own include Matinas BioPharma (MTNB), Bionano Genomics (BNGO), ADMA Biologics (ADMA), Novan (NOVN), Zosano Pharma (ZSAN), Gran Tierra Energy (GTE), Cogent Biosciences (UMRX), Aeterna Zentaris (AEZS), Sorrento Therapeutics (SRNE) and Enerplus (ERF). This page (NASDAQ:DFFN) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Diffusion Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
